Stock Track | Poseida Therapeutics Soars 224.65% As Roche's $1.5 Billion Acquisition Bolsters Cell Therapy Capabilities

Stock Track

Nov 26, 2024

During the pre-market session on Tuesday, shares of Poseida Therapeutics, Inc. (PSTX) skyrocketed by 224.65%, fueled by the announcement of a merger agreement to be acquired by Roche Holdings, Inc. in a deal valued at up to $1.5 billion on a fully diluted basis.

Under the terms of the agreement, Roche will launch a tender offer to acquire all outstanding shares of Poseida for $9.00 per share in cash, plus a non-tradeable contingent value right (CVR) to receive up to an additional $4.00 per share in cash upon achieving specific milestones. The transaction is expected to close in the first quarter of 2025.

The acquisition aims to establish a new core capability for Roche in allogeneic cell therapy, with lead opportunities focused on the existing strategic collaboration between Poseida and Roche in hematologic malignancies. It will also include Poseida's CAR-T programs for solid tumors and autoimmune diseases, its genetic engineering platform, and related preclinical medicines.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1170802876"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1170802876\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1170802876?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-26 23:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170802876","market":"us","top_or_hot":-1,"title":"Stock Track | Poseida Therapeutics Soars 224.65% As Roche's $1.5 Billion Acquisition Bolsters Cell Therapy Capabilities","media":"Stock Track","content":"<p>During the pre-market session on Tuesday, shares of Poseida Therapeutics, Inc. (PSTX) skyrocketed by 224.65%, fueled by the announcement of a merger agreement to be acquired by Roche Holdings, Inc. in a deal valued at up to $1.5 billion on a fully diluted basis.</p>\n\n<p>Under the terms of the agreement, Roche will launch a tender offer to acquire all outstanding shares of Poseida for $9.00 per share in cash, plus a non-tradeable contingent value right (CVR) to receive up to an additional $4.00 per share in cash upon achieving specific milestones. The transaction is expected to close in the first quarter of 2025.</p>\n\n<p>The acquisition aims to establish a new core capability for Roche in allogeneic cell therapy, with lead opportunities focused on the existing strategic collaboration between Poseida and Roche in hematologic malignancies. It will also include Poseida's CAR-T programs for solid tumors and autoimmune diseases, its genetic engineering platform, and related preclinical medicines.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Poseida Therapeutics Soars 224.65% As Roche's $1.5 Billion Acquisition Bolsters Cell Therapy Capabilities</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Poseida Therapeutics Soars 224.65% As Roche's $1.5 Billion Acquisition Bolsters Cell Therapy Capabilities\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-26 23:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>During the pre-market session on Tuesday, shares of Poseida Therapeutics, Inc. (PSTX) skyrocketed by 224.65%, fueled by the announcement of a merger agreement to be acquired by Roche Holdings, Inc. in a deal valued at up to $1.5 billion on a fully diluted basis.</p>\n\n<p>Under the terms of the agreement, Roche will launch a tender offer to acquire all outstanding shares of Poseida for $9.00 per share in cash, plus a non-tradeable contingent value right (CVR) to receive up to an additional $4.00 per share in cash upon achieving specific milestones. The transaction is expected to close in the first quarter of 2025.</p>\n\n<p>The acquisition aims to establish a new core capability for Roche in allogeneic cell therapy, with lead opportunities focused on the existing strategic collaboration between Poseida and Roche in hematologic malignancies. It will also include Poseida's CAR-T programs for solid tumors and autoimmune diseases, its genetic engineering platform, and related preclinical medicines.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PSTX","symbol_name":"Poseida Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1170802876","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170802876","pubTimestamp":1732633355,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"During the pre-market session on Tuesday, shares of Poseida Therapeutics, Inc.  skyrocketed by 224.65%, fueled by the announcement of a merger agreement to be acquired by Roche Holdings, Inc. in a deal valued at up to $1.5 billion on a fully diluted basis.Under the terms of the agreement, Roche will launch a tender offer to acquire all outstanding shares of Poseida for $9.00 per share in cash, plus a non-tradeable contingent value right  to receive up to an additional $4.00 per share in cash upo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PSTX":"Poseida Therapeutics, Inc."},"translate_title":"罗氏15亿美元收购增强细胞治疗能力，股票赛道Poseida Therapeutics飙升224.65%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PSTX":1},"content_text":"During the pre-market session on Tuesday, shares of Poseida Therapeutics, Inc. (PSTX) skyrocketed by 224.65%, fueled by the announcement of a merger agreement to be acquired by Roche Holdings, Inc. in a deal valued at up to $1.5 billion on a fully diluted basis.\nUnder the terms of the agreement, Roche will launch a tender offer to acquire all outstanding shares of Poseida for $9.00 per share in cash, plus a non-tradeable contingent value right (CVR) to receive up to an additional $4.00 per share in cash upon achieving specific milestones. The transaction is expected to close in the first quarter of 2025.\nThe acquisition aims to establish a new core capability for Roche in allogeneic cell therapy, with lead opportunities focused on the existing strategic collaboration between Poseida and Roche in hematologic malignancies. It will also include Poseida's CAR-T programs for solid tumors and autoimmune diseases, its genetic engineering platform, and related preclinical medicines.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}